{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:12:23Z","timestamp":1789564343512,"version":"build-2803163510"},"reference-count":25,"publisher":"Harborside Press, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Treatment-free remission (TFR) has become a treatment goal for chronic myeloid leukemia (CML). This study aimed to define precise conditions for treatment discontinuation and to develop TFR prediction models in a Chinese population.\n                    <jats:bold>Patients and Methods:<\/jats:bold>\n                    This study collected data from 11 centers involving 802 cases of tyrosine kinase inhibitor (TKI) discontinuation in patients with CML. Eligible patients had received any TKI for at least 3 years and had maintained a deep molecular response (DMR) for at least 2 years. The primary endpoint was maintenance of major molecular response (MMR) within 12 months after discontinuation.\n                    <jats:bold>Results:<\/jats:bold>\n                    Among 698 eligible patients (459 in the learning cohort and 239 in the validation cohort), 318 (45.6%) lost MMR, most commonly within the first 6 months after discontinuation (234\/318; 73.6%). TFR rates were 66.5% at 6 months, 57.7% at 12 months, and 55.5% at 24 months. All patients regained MMR\/DMR upon TKI reinitiation, with no disease progression. Longer treatment duration and sustained DMR were associated with higher TFR rates for both imatinib and second-generation TKIs. Superior outcomes correlated with low Sokal risk, no resistance, \u22655 years of TKI therapy, optimal DMR duration, and achievement of MMR at 12 months. The rate of sustained TFR was 73.5%, 60.0%, 44.6%, and 20.6% for patients with 0, 1, 2, and \u22653 nonoptimal factors, respectively. We developed predictive models and created a web-based calculator to assist clinicians in decision-making.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Patients achieving durable DMR can safely discontinue therapy with rigorous monitoring. TFR attempts remain viable even under nonoptimal conditions, provided that adequate DMR duration and close monitoring are maintained.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2026.7026","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:55:21Z","timestamp":1784638521000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia"],"prefix":"10.6004","volume":"24","author":[{"given":"Fang","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, Hubei, China"},{"name":"Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostic Group Co., Ltd., Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Provincial People\u2019s Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Guangdong Provincial People\u2019s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First People\u2019s Hospital of Jingzhou, Jingzhou, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanling","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajuan","family":"Ke","sequence":"additional","affiliation":[{"name":"Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostic Group Co., Ltd., Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyan","family":"Wu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostic Group Co., Ltd., Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People\u2019s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen University School of Medicine, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People\u2019s Hospital, Beijing, China"},{"name":"Peking University People\u2019s Hospital, Qingdao, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"JAMA","first-page":"1618","article-title":"Chronic myeloid leukemia: a review","volume":"333","author":"Jabbour E","year":"2025","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: a review. JAMA 2025;333:1618\u20131629."},{"key":"B2","series-title":"Blood Lymphat Cancer","first-page":"1","article-title":"How I manage patients with chronic myeloid leukemia (CML): perspectives from clinical practice","volume":"12","author":"Guru Murthy GS","year":"2022","unstructured":"Guru Murthy GS. How I manage patients with chronic myeloid leukemia (CML): perspectives from clinical practice. Blood Lymphat Cancer 2022;12:1\u20136."},{"key":"B3","series-title":"Am J Hematol","first-page":"2191","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour E","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol 2024;99:2191\u20132212."},{"key":"B4","series-title":"Blood Cancer J","first-page":"58","article-title":"Management of chronic myeloid leukemia in 2023 - common ground and common sense","volume":"13","author":"Senapati J","year":"2023","unstructured":"Senapati J, Sasaki K, Issa GC,  Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J 2023;13:58."},{"key":"B5","series-title":"Leukemia","first-page":"1056","article-title":"Living, not just surviving, with chronic myeloid leukemia - quality of life to the front of the line","volume":"39","author":"Lipton JH","year":"2025","unstructured":"Lipton JH, Rea D. Living, not just surviving, with chronic myeloid leukemia - quality of life to the front of the line. Leukemia 2025;39:1056\u20131057."},{"key":"B6","series-title":"Blood","first-page":"921","article-title":"The evolution of treatment-free remission","volume":"145","author":"Hughes TP","year":"2025","unstructured":"Hughes TP, Yong AS, Ross DM. The evolution of treatment-free remission. Blood 2025;145:921\u2013930."},{"key":"B7","series-title":"Lancet Oncol","first-page":"1029","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon FX","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J,  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029\u20131035."},{"key":"B8","series-title":"Blood","first-page":"515","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross DM","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF,  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515\u2013522."},{"key":"B9","series-title":"JAMA Oncol","first-page":"42","article-title":"Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial","volume":"7","author":"Atallah E","year":"2021","unstructured":"Atallah E, Schiffer CA, Radich JP,  Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol 2021;7:42\u201350."},{"key":"B10","series-title":"Lancet Oncol","first-page":"747","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele S","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J,  Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 2018;19:747\u2013757."},{"key":"B11","series-title":"Clin Cancer Res","first-page":"6606","article-title":"Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients","volume":"25","author":"Nicolini FE","year":"2019","unstructured":"Nicolini FE, Dulucq S, Boureau L,  Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients. Clin Cancer Res 2019;25:6606\u20136613."},{"key":"B12","series-title":"J Clin Oncol","first-page":"1875","article-title":"European Stop Tyrosine Kinase Inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission","volume":"42","author":"Mahon FX","year":"2024","unstructured":"Mahon FX, Pfirrmann M, Dulucq S,  European Stop Tyrosine Kinase Inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission. J Clin Oncol 2024;42:1875\u20131880."},{"key":"B13","article-title":"NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 2.2024","author":"Shah NP","unstructured":"Shah NP, Bhatia R, Altman JK,  NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 2.2024. Accessed March 10, 2026. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B14","series-title":"Leukemia","first-page":"1797","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley JF","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP,  2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia 2025;39:1797\u20131813."},{"key":"B15","series-title":"Blood","first-page":"846","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea D","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M,  Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 2017;129:846\u2013854."},{"key":"B16","series-title":"Protein Cell","first-page":"403","article-title":"Leukemia stem cells: the root of chronic myeloid leukemia","volume":"6","author":"Zhou H","year":"2015","unstructured":"Zhou H, Xu R. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell 2015;6:403\u2013412."},{"key":"B17","series-title":"Am J Hematol","first-page":"1762","article-title":"Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: final analysis of the TFR-PRO study","volume":"98","author":"Zambrotta GPM","year":"2023","unstructured":"Zambrotta GPM, Nicolini FE, Assouline S,  Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: final analysis of the TFR-PRO study. Am J Hematol 2023;98:1762\u20131771."},{"key":"B18","series-title":"Blood Cancer J","first-page":"53","article-title":"A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements","volume":"14","author":"Bonifacio M","year":"2024","unstructured":"Bonifacio M, Scaffidi L, Miggiano MC,  A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements. Blood Cancer J 2024;14:53."},{"key":"B19","series-title":"J Clin Med","first-page":"2567","article-title":"Treatment-free remission in chronic myeloid leukemia","volume":"13","author":"Bourne G","year":"2024","unstructured":"Bourne G, Bhatia R, Jamy O. Treatment-free remission in chronic myeloid leukemia. J Clin Med 2024;13:2567."},{"key":"B20","series-title":"Leukemia","first-page":"810","article-title":"Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukaemia","volume":"39","author":"Gong X","year":"2025","unstructured":"Gong X, Zhai X, Shen Q,  Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukaemia. Leukemia 2025;39:810\u2013815."},{"key":"B21","series-title":"J Natl Compr Canc Netw","first-page":"1421","article-title":"Treatment outcomes in chronic myeloid leukemia: does one size fit all?","volume":"18","author":"Garcia-Horton A","year":"2020","unstructured":"Garcia-Horton A, Lipton JH. Treatment outcomes in chronic myeloid leukemia: does one size fit all? J Natl Compr Canc Netw 2020;18:1421\u20131428."},{"key":"B22","series-title":"Br J Haematol","first-page":"434","article-title":"How to improve treatment-free remission eligibility in chronic myeloid leukaemia?","volume":"204","author":"Costa A","year":"2024","unstructured":"Costa A, Breccia M. How to improve treatment-free remission eligibility in chronic myeloid leukaemia? Br J Haematol 2024;204:434\u2013448."},{"key":"B23","series-title":"J Natl Compr Canc Netw","first-page":"e247044","article-title":"Dose modifications in the management of chronic phase chronic myeloid leukemia: who, what, and when","volume":"22","author":"Oehler VG","year":"2024","unstructured":"Oehler VG, Huang IJ, Siu C,  Dose modifications in the management of chronic phase chronic myeloid leukemia: who, what, and when. J Natl Compr Canc Netw 2024;22:e247044."},{"key":"B24","series-title":"Blood","first-page":"2701","article-title":"Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter?","volume":"145","author":"Dalgetty M","year":"2025","unstructured":"Dalgetty M, Cortes J. Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter? Blood 2025;145:2701\u20132708."},{"key":"B25","series-title":"Cancers (Basel)","first-page":"e247044","article-title":"Real-world evidence of treatment-free remission strategies and outcomes in chronic myeloid leukemia","volume":"17","author":"Bourne G","year":"2025","unstructured":"Bourne G, Diebold K, Bascug G,  Real-world evidence of treatment-free remission strategies and outcomes in chronic myeloid leukemia. Cancers (Basel) 2025;17:e247044."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/9\/article-e267026.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/9\/article-e267026.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/9\/article-e267026.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:52:46Z","timestamp":1789563166000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/9\/article-e267026.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":25,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.7026","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}